Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

Cisplatin, carboplatin, and oxaliplatin are three FDA-approved members of the platinum
anticancer drug family. These compounds induce apoptosis in tumor cells by binding to …

Ruthenium compounds have become promising alternatives to platinum drugs by displaying
specific activities against different cancers and favourable toxicity and clearance properties …

Interest in the medicinal properties of ruthenium (II)–arene compounds has grown rapidly
over the last decade. In this account we describe the origins of the field and subsequently …

A theranostic agent combines diagnostic reporter with therapeutic activity in a single entity,
an approach that seeks to increase the efficacy of cancer treatment. Herein, we describe the …

When cisplatin was first synthesized, over 150 years ago, inorganic chemistry was in its
infancy and no one would have foreseen a role in medicine. Some 120 years later …

A critical discussion is presented about the possible role of Pt–protein interactions in the
mechanisms of action of platinum anticancer compounds. Although, since 40 years from its …

Response rates to conventional chemotherapeutics remain unsatisfactory for hepatocellular
carcinoma (HCC) due to the high rates of chemoresistance and recurrence. Tumor-initiating …

The organometallic ruthenium (II)[Ru (arene) Cl2PTA] PTA‐1, 3, 5‐triaza‐7‐
phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer …

Many transition metal complexes have unique physicochemical properties that can be
efficiently exploited in medicinal chemistry for cancer treatment. Traditionally, double …